Home > Academic Announcements > (Jul. 18) Frontiers in Medical Sciences Lecture Series 343: CRISPR-based CAR T cell engineering and automated manufacture

(Jul. 18) Frontiers in Medical Sciences Lecture Series 343: CRISPR-based CAR T cell engineering and automated manufacture

Last updated :2018-07-12

Topic: CRISPR-based CAR T cell engineering and automated manufacture
Speaker: Jiangtao Ren
, PhD, partner and chief scientist, Nanjing Bioheng Biotechnology
Chair: Guangmei Yan, Ph.D. & Professor, Zhongshan School of Medicine, SYSU
Time: 10:00 am, Wednesday, July 18, 2018
Venue: Lecture Hall, 4th Floor, Yongsheng Building, Guangzhou North Campus, SYSU

About the speaker:
Jiangtao Ren, Ph.D., partner and chief scientist of Nanjing Bioheng Biotechnology, graduated from Shanghai Institute of Biochemistry and Cell Biology. He has served in Novartis Pharmaceuticals and TCR2 Therapeutics successively.

Dr. Ren has been engaged in the research of allogeneic stem cell transplantation and allogeneic universal CAR-T cells for many years. He was taught by Professor Carl June, a pioneer of CAR-T therapy and academician of the American Academy of Arts and Sciences, to carry out research on tumor immunotherapy and postdoctoral training on clinical transformation. Dr. Ren successfully prepared generic CAR-T cells for the first time in the world using crispr gene editing technology. This work is the cornerstone of the first crispr clinical experiment in the United States conducted by the University of Pennsylvania. At the same time, Dr. Ren used crispr technology to screen the whole genome of the pathways that affect the function of CAR-T cells, and discovered key genes that regulate the effect of immunotherapy, which provided a strong basis for improving the therapeutic effect of car - t cells and discovering new immune checkpoints.

Dr. Ren has been engaged in CAR-T cell research at the University of Pennsylvania and TCR2 Therapeutics for many years. He has rich experience in semi-automatic and automatic production. He has successfully combined clinical crispr gene editing with CAR-T and TCR-T production organically, and has established a general CAR-T and TCR-T cell production process that meets industrial standards, laying a foundation for the industrialization and standardization of cell immunotherapy.